Non-peptidic GnRH receptor antagonists

Review OA: closed public-domain-us
Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-23 ⓘ

This review examines the medicinal chemistry and structure-activity relationships of non-peptidic GnRH receptor antagonists, small molecules designed to overcome the poor oral bioavailability of peptidic agents used in treating conditions like endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-06 · read from full text ⓘ

This review article examines the medicinal chemistry and structure-activity relationships of non-peptidic antagonists targeting the gonadotropin-releasing hormone receptor. It contrasts these small molecule candidates with existing peptidic agonists and antagonists, highlighting the potential for improved oral bioavailability in therapeutic applications such as prostate cancer, breast tumors, uterine fibroids, precocious puberty, and infertility. The authors note that while peptidic agents are currently limited to parenteral administration due to poor oral availability, several small molecule series offer promising alternatives for systemic delivery. Relevance to endometriosis: listed as one indication for GnRH antagonists, though the paper's main focus is uterine fibroids.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Gonadotropin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LHRH) is a decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) hypothalamic hormone that acts upon 7-trans membrane spanning GnRH receptors in the pituitary. This action leads to the secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) that in turn act on the reproductive organs regulating gonadal steroid production, spermatogenesis and follicular development. Peptidic agonists of the GnRH receptor have been known for many years and are currently employed therapeutically in the treatment of prostate and breast tumours, uterine fibroids, precocious puberty, endometriosis, premenstrual syndrome, contraception and infertility. Peptidic antagonists to date have only been employed commercially in the treatment of infertility during assisted reproductive therapy; however, many peptidic antagonists are currently in late stage development for many of the aforementioned indications. Whilst peptidic agonists and antagonists of the GnRH receptor have been discovered and exploited clinically, they are limited to predominantly parenteral administration due to their poor oral bioavailability. Recently, several small molecule GnRH antagonist series have been discovered offering the prospect of orally active therapeutics based on GnRH receptor antagonism. This article will review the current medicinal chemistry literature and structure activity relationships known for non-peptidic GnRH receptor antagonists.
Full text 7,243 characters · extracted from oa-doi-fallback · 3 sections · click to expand

Abstract

Keywords: gnrh, lhrh, agonist, antagonist, non-peptidic Current Medicinal Chemistry Title: Non-Peptidic GnRH Receptor Antagonists Volume: 11 Issue: 22 Author(s): Richard E. Armer and Kathryn H. Smelt Affiliation:

Keywords

gnrh, lhrh, agonist, antagonist, non-peptidic

Abstract

Gonadotropin-releasing hormone (GnRH) or luteinizing hormone-releasing hormone (LHRH) is a decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) hypothalamic hormone that acts upon 7-trans membrane spanning GnRH receptors in the pituitary. This action leads to the secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) that in turn act on the reproductive organs regulating gonadal steroid production, spermatogenesis and follicular development. Peptidic agonists of the GnRH receptor have been known for many years and are currently employed therapeutically in the treatment of prostate and breast tumours, uterine fibroids, precocious puberty, endometriosis, premenstrual syndrome, contraception and infertility. Peptidic antagonists to date have only been employed commercially in the treatment of infertility during assisted reproductive therapy; however, many peptidic antagonists are currently in late stage development for many of the aforementioned indications. Whilst peptidic agonists and antagonists of the GnRH receptor have been discovered and exploited clinically, they are limited to predominantly parenteral administration due to their poor oral bioavaila bility. Recently, several small molecule GnRH antagonist series have been discovered offering the prospect of orally active therapeutics based on GnRH receptor antagonism. This article will review the current medicinal chemistry literature and structure activity relationships known for non-peptidic GnRH receptor antagonists. Export Options About this article Cite this article as: Armer E. Richard and Smelt H. Kathryn, Non-Peptidic GnRH Receptor Antagonists, Current Medicinal Chemistry 2004; 11 (22) . https://dx.doi.org/10.2174/0929867043363983 | DOI https://dx.doi.org/10.2174/0929867043363983 | Print ISSN 0929-8673 | | Publisher Name Bentham Science Publishers | Online ISSN 1875-533X | Call for Papers in Thematic Issues Advance in Novel Drug and combined Therapies for Chronic Diseases Chronic diseases such as malignant tumors and rheumatoid arthritis have long plagued a large number of patients. Currently, the management of chronic diseases has entered a new stage of targeted regulation, precise intervention and integrated treatment. The traditional diagnosis and treatment model is undergoing profound changes due to new drugs ...read more Advances in Computational Strategies for Neurodegenerative Disorders, Cancer, and Infectious Diseases” This thematic issue highlights recent advances in computational strategies applied to neurodegenerative disorders, cancer, and infectious diseases. It focuses on the use of artificial intelligence, machine learning, molecular modeling, molecular dynamics simulations, bioinformatics, and multi-omics data analysis to understand disease mechanisms and accelerate drug discovery. The contributions demonstrate how computational ...read more AI-Assisted Medicinal Chemistry and Bioactive Delivery Systems for Tissue Engineering and Regenerative Medicine The proposed Mini-Thematic Issue aims to highlight recent advances at the interface of medicinal chemistry, artificial intelligence-assisted drug design, bioactive biomaterials, and regenerative medicine. With the rapid development of computational chemistry, quantitative structure–activity/structure–function relationship analysis, molecular docking, molecular dynamics simulation, high-throughput screening, and machine learning-based prediction models, medicinal chemistry is ...read more Artificial Intelligence Empowers the Research and Development of Anti-Infective Drugs: From Target Discovery and Molecular Design to Clinical Translation The global crisis of drug resistance in bacteria, viruses, fungi, and parasites is becoming increasingly severe. Traditional anti-infective drug development faces bottlenecks such as long cycles, high costs, low success rates, and a shortage of novel structures. Artificial intelligence (AI) and machine learning are fundamentally reshaping the drug discovery and ...read more - Author Guidelines - Bentham Author Support Services (BASS) - Graphical Abstracts - Fabricating and Stating False Information - Research Misconduct - Post Publication Discussions and Corrections - Publishing Ethics and Rectitude - Increase Visibility of Your Article - Archiving Policies - Peer Review Workflow - Order Your Article Before Print - Promote Your Article - Manuscript Transfer Facility - Editorial Policies - Allegations from Whistleblowers - Announcements Related Articles Mini-Reviews in Medicinal Chemistry New Targeted Therapies for Anaplastic Thyroid Cancer Anti-Cancer Agents in Medicinal Chemistry A Review on Structures and Functions of Bcl-2 Family Proteins from Homo sapiens Protein & Peptide Letters Influence of Tumor Microenvironment on the Distribution and Elimination of Nano-formulations Current Drug Metabolism Liposomes Prepared in Absence of Organic Solvents: Sonication Versus Lipid Film Hydration Method Current Pharmaceutical Analysis Protective Effects of Curcumin against Iron-induced Toxicity Current Pharmaceutical Biotechnology Hormonal Effects on Drug Metabolism Through the CYP System: Perspectives on Their Potential Significance in the Era of Pharmacogenomics Current Drug Targets - Immune, Endocrine & Metabolic Disorders Aptamers: Molecular Tools for Medical Diagnosis Current Topics in Medicinal Chemistry Evolution of Novel Non-Steroidal Anti-Inflammatory Drugs with Reduced Gastrointestinal Adverse Effects Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells Current Pharmaceutical Design Treatment of Metastases to the Vertebrae with Radiofrequency Ablation: Determination of Effectiveness by Evaluation of Tumor Necrosis – A Preliminary Result Current Radiopharmaceuticals Synthesis and Cytotoxic Activity of New β-Carboline Derivatives Mini-Reviews in Medicinal Chemistry Properties and Recent Advantages of N,N’-dialkylimidazolium-ion Liquids Application in Electrochemistry Current Analytical Chemistry Recent Advances of Sulfonylation Reactions in Water Current Organic Synthesis Inhibitors of Vascular Endothelial Growth Factor in Cancer Cardiovascular & Hematological Agents in Medicinal Chemistry Open Questions on Bioequivalence: An Updated Reappraisal Current Clinical Pharmacology Small Molecule Inhibitors of Stat3 Signaling Pathway Current Cancer Drug Targets Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects Current Molecular Medicine Glycosides from Medicinal Plants as Potential Anticancer Agents: Emerging Trends Towards Future Drugs Current Medicinal Chemistry 18F-labeled Bisphosphonate as an Alternative Candidate to the Gold Standard[18F]sodium fluoride ([18F]NaF) for PET Bone Imaging Current Medical Imaging

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisinfertility

MeSH descriptors

Receptors, LHRH Administration, Oral Administration, Oral Animals Animals Antineoplastic Agents Antineoplastic Agents Antineoplastic Agents Antineoplastic Agents Clinical Trials as Topic Clinical Trials as Topic Female Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Hormone Antagonists Hormone Antagonists Hormone Antagonists Hormone Antagonists

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-08T06:18:23.926119+00:00
pubmed
last seen: 2026-10-08T21:02:47.667321+00:00
unpaywall
last seen: 2026-10-08T06:33:43.470499+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine